Aligos Therapeutics (ALGS) to Release Quarterly Earnings on Wednesday

Key Points

• Aligos Therapeutics is expected to announce its Q2 2025 earnings on August 5, forecasting a loss of ($2.35) per share and revenue of $0.43 million.
• The company recently reported a loss of ($2.11) per share in its last quarter, beating expectations but had a negative net margin of 1,628.75%.
• An institutional investor, Woodline Partners LP, has acquired a new stake worth approximately $2.6 million, increasing the total institutional ownership of the stock to 60.43%.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) is expected to be announcing its Q2 2025 earnings results after the market closes on Wednesday, August 6th. Analysts expect the company to announce earnings of ($2.35) per share and revenue of $0.43 million for the quarter.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($2.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.80) by $0.69. Aligos Therapeutics had a positive return on equity of 14.67% and a negative net margin of 1,628.75%. The business had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.33 million. On average, analysts expect Aligos Therapeutics to post $-10 EPS for the current fiscal year and $-12 EPS for the next fiscal year.

Aligos Therapeutics Stock Performance

ALGS traded up $0.12 on Friday, hitting $7.40. 30,977 shares of the company were exchanged, compared to its average volume of 179,750. Aligos Therapeutics has a 12 month low of $3.76 and a 12 month high of $46.80. The company has a market cap of $45.21 million, a PE ratio of -0.42 and a beta of 2.77. The stock's fifty day moving average is $7.60 and its 200-day moving average is $11.65.

Institutional Trading of Aligos Therapeutics

A hedge fund recently bought a new stake in Aligos Therapeutics stock. Woodline Partners LP purchased a new position in shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 315,383 shares of the company's stock, valued at approximately $2,602,000. Woodline Partners LP owned about 5.16% of Aligos Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 60.43% of the company's stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).